Compare Nutanix Inc (NTNX) vs Novartis AG (NVS) Price & Performance

Nutanix (NTNX) trades at $67.49, down 0.84% on the day, but maintains a bullish technical outlook with strong support near $66. The company reported robust Q4 2026 earnings, beating EPS estimates with $0.60 versus $0.49 expected, and revenue growth continues to accelerate. Analyst sentiment is overwhelmingly positive with a consensus price target of $77.20 and no sell ratings among 32 analysts covering the stock.

The outlook remains favorable given consistent earnings beats and recognition in Gartner's Magic Quadrant. Key risks include high valuation multiples like EV/EBITDA of 50.5 and competitive pressures in cloud infrastructure. The stock offers upside to consensus targets but requires monitoring of execution against growth expectations.

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.